Dacarbazine

"Dacarbazine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)

Descriptor ID	D003606
MeSH Number(s)	D02.925.200 D03.383.129.308.240
Concept/Terms	Dacarbazine Dacarbazine Dimethyl Imidazole Carboxamide Carboxamide, Dimethyl Imidazole Imidazole Carboxamide, Dimethyl DTIC ICDT Decarbazine 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide DIC Dimethyl Triazeno Imidazole Carboxamide NSC-45388 NSC-45388 NSC 45388 NSC45388 DTIC-Dome DTIC-Dome DTIC Dome DTICDome Biocarbazine Biocarbazine Deticene Deticene

Below are MeSH descriptors whose meaning is more general than "Dacarbazine".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Triazenes [D02.925]
Dacarbazine [D02.925.200]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Azoles [D03.383.129]
Imidazoles [D03.383.129.308]
Dacarbazine [D03.383.129.308.240]

Below are MeSH descriptors whose meaning is more specific than "Dacarbazine".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Dacarbazine" by people in this website by year, and whether "Dacarbazine" was a major or minor topic of these publications.

Bar chart showing 256 publications over 30 distinct years, with a maximum of 23 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1990	0	2	2
1991	0	1	1
1992	0	2	2
1993	0	3	3
1994	0	5	5
1995	1	2	3
1996	0	1	1
1997	0	2	2
1998	0	5	5
1999	0	1	1
2000	4	1	5
2001	2	0	2
2002	1	8	9
2003	5	1	6
2004	7	0	7
2005	4	2	6
2006	7	9	16
2007	6	6	12
2008	4	19	23
2009	7	7	14
2010	6	8	14
2011	5	9	14
2012	5	6	11
2013	6	12	18
2014	6	10	16
2015	10	7	17
2016	6	8	14
2017	9	9	18
2018	1	7	8
2019	1	0	1

Below are the most recent publications written about "Dacarbazine" by people in Profiles.

Patel S, von Mehren M, Reed DR, Kaiser P, Charlson J, Ryan CW, Rushing D, Livingston M, Singh A, Seth R, Forscher C, D'Amato G, Chawla SP, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Demetri GD. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer. 2019 08 01; 125(15):2610-2620.

View in: PubMed
Wong WJ, Ruhangaza D, Manirakiza A, Omondi J, Mugabe MC, Isabelle I, Morgan EA, Aster JC. Concomitant classic Hodgkin lymphoma and schistosomiasis. Am J Hematol. 2019 07; 94(7):840-841.

View in: PubMed
Strati P, Fanale MA, Oki Y, Turturro F, Fayad LE, Bartlett NL, Gladstone DE, Kasamon YL, Portlock CS, Wilson WH, Goy A, Younes A, Lee HJ. ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study. Haematologica. 2019 02; 104(2):e65-e67.

View in: PubMed
Evens AM, Advani RH, Helenowski IB, Fanale M, Smith SM, Jovanovic BD, Bociek GR, Klein AK, Winter JN, Gordon LI, Hamlin PA. Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. J Clin Oncol. 2018 10 20; 36(30):3015-3022.

View in: PubMed
Ozuah NW, Marcus KJ, LaCasce AS, Billett AL. Excellent Outcomes Following Response-based Omission of Radiotherapy in Children and Adolescents With Intermediate or High-risk Hodgkin Lymphoma. J Pediatr Hematol Oncol. 2018 08; 40(6):e338-e342.

View in: PubMed
Harrison RA, de Groot JF. Treatment of Glioblastoma in the Elderly. Drugs Aging. 2018 Aug; 35(8):707-718.

View in: PubMed
Pinnix CC, Wirth A, Milgrom SA, Andraos TY, Aristophanous M, Pham M, Hancock D, Ludmir EB, Gunther JR, Fanale MA, Oki Y, Nastoupil L, Chuang HH, Mikhaeel NG, Dabaja BS. Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy. Leuk Lymphoma. 2018 11; 59(11):2650-2659.

View in: PubMed
Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O'Brien S, Kantarjian H. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):230-234.

View in: PubMed
Ghia AJ. Fractionated Radiotherapy of Intracranial Gliomas. Prog Neurol Surg. 2018; 31:38-47.

View in: PubMed
Milgrom SA, Pinnix CC, Gunther JR, Fanale M, Dabaja BS. Post-ABVD biopsy results, and not post-ABVD FDG-PET results, predict outcome in early-stage Hodgkin lymphoma: response to Adams and Kwee. Br J Haematol. 2019 01; 184(2):292-293.

View in: PubMed

People

Explore

Similar Concepts

Top Journals